SEC Form 4 · accession 0001470831-26-000897
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Kumar
Officer — Chief Executive Officer · Director
Period of report
Sep 17, 2026
Accepted (ET)
Sep 21, 2026 · 6:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 17, 2026 | S | 8,721 | $69.0136 | D | 496,965 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Common StockF4,F3 | Sep 17, 2026 | S | 1,279 | $69.5696 | D | 495,686 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Common StockF3 | holding | — | — | — | 3,568,447 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | |
| Common StockF5 | holding | — | — | — | 750,000 | I | By NK 2026 GRAT | |
| Common Stock | holding | — | — | — | 243,327 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
- F2Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- F4Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F5These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.